FUKOKU MUTUAL LIFE INSURANCE Co Has $18.13 Million Stake in Pfizer Inc. $PFE

FUKOKU MUTUAL LIFE INSURANCE Co lowered its stake in Pfizer Inc. (NYSE:PFE) by 0.5% in the second quarter, Holdings Channel reports. The fund owned 748,076 shares of the biopharmaceutical company’s stock after selling 3,822 shares during the quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Pfizer were worth $18,133,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PFE. Howe & Rusling Inc. increased its position in Pfizer by 2.8% during the 2nd quarter. Howe & Rusling Inc. now owns 29,599 shares of the biopharmaceutical company’s stock worth $717,000 after purchasing an additional 799 shares in the last quarter. Miller Financial Services LLC boosted its position in Pfizer by 4.8% in the second quarter. Miller Financial Services LLC now owns 18,193 shares of the biopharmaceutical company’s stock valued at $441,000 after buying an additional 830 shares in the last quarter. Empirical Finance LLC grew its stake in shares of Pfizer by 0.6% during the second quarter. Empirical Finance LLC now owns 197,247 shares of the biopharmaceutical company’s stock worth $4,781,000 after buying an additional 1,228 shares during the last quarter. VSM Wealth Advisory LLC increased its holdings in shares of Pfizer by 90.8% during the second quarter. VSM Wealth Advisory LLC now owns 6,104 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 2,905 shares in the last quarter. Finally, Stonebrook Private Inc. acquired a new position in shares of Pfizer during the second quarter worth $234,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Morgan Stanley lowered their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Scotiabank began coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Price Performance

Shares of PFE opened at $24.93 on Thursday. The business has a 50-day moving average of $24.83 and a 200-day moving average of $24.47. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $141.74 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.